Zoetis has announced the acquisition of Jurox, a privately owned Australian animal health company that develops, manufactures and markets a wide range of veterinary medicines for treating livestock and companion animals.

While its operations are based in Australia, Jurox also has regional offices in New Zealand, U.S., Canada and the UK. Financial terms of the transaction, which was announced in August 2021, are not being disclosed.

The acquisition of Jurox brings Zoetis a range of important products primed for greater global expansion; a valuable animal health portfolio, including Alfaxan, a leading anaesthetic product for companion animals; and high-quality local R&D and manufacturing operations.

Australia was Zoetis’ fourth largest market based on revenue in 2021.

“We are grateful to the O’Brien family for entrusting the future of this family-owned business to Zoetis,” said Zoetis CEO Kristin Peck.

“Jurox’s portfolio plays to the strengths of our core business and will be a complementary fit with the solutions we deliver to veterinary professionals, livestock producers and pet owners around the world,” Ms Peck said.

“With Zoetis’ global sales and regulatory expertise in more than 45 markets, we look forward to expanding the impact and reach of the entire Jurox portfolio.”

Jurox develops and manufactures more than 150 products in areas such as parasiticides, anti-infectives, anaesthesia, cardiology and reproduction for animals.

Founded in 1992, Jurox formulates, manufactures and distributes companion and commercial animal health products from its CGMP-compliant facility located in the NSW Hunter Valley. Jurox products, including a leading anaesthetic product Alfaxan, are currently distributed Australia, the US and more than 20 other countries around the world.